---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-141614"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2021-11-19T23:59:59+00:00"
generated_at: "2026-06-28T06:35:13.427968+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Voyager CFO Allison Dorval resigns; Julie Burek appointed CFO effective Nov 26, 2021

## Summary
- Allison Dorval resignation as CFO effective Nov 26, 2021, to pursue role at another company.
- Dorval to enter separation agreement and consulting contract through Jan 14, 2022.
- During consulting period, existing RSUs and stock options continue vesting as if employed.
- Julie Burek, VP of Finance since Aug 2020, appointed principal financial and accounting officer.
- Burek receives option for 25,000 shares effective Nov 26, 2021, and RSU for 13,500 shares effective Jan 1, 2022.

## SEC filing metadata
- accession: 0001104659-21-141614
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2021-11-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465921141614/0001104659-21-141614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465921141614/tm2133470d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-141614
- JSON: https://secwatch.observer/filing/0001104659-21-141614.json
- Plain text: https://secwatch.observer/filing/0001104659-21-141614.txt

## Key facts
- Executive change
  Allison Dorval resigned as Chief Financial Officer at Voyager Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Allison Dorval notified Voyager Therapeutics, Inc. (the "Company") of her resignation as Chief Financial Officer of the Company, effective November 26, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465921141614/0001104659-21-141614-index.htm
- Executive change
  Julie Burek was appointed as principal financial officer and principal accounting officer at Voyager Therapeutics, Inc..
  - Action: appointed
  - Role: principal financial officer and principal accounting officer
  source text: the board of directors of the Company (the "Board") has appointed Julie Burek to assume the roles of principal financial officer and principal accounting officer of the Company, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465921141614/0001104659-21-141614-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.